Friday, March 25, 2022

ZEEL

ZEEL(Zee Entertainment Enterprises Limited)

07.12.2022 - CLSA on ZEEL Maintain Buy CMP 260.9 Target 325
14.11.2022 - UBS on ZEEL Maintain Buy CMP 259.2 Target 350
16.08.2022 - CLSA on ZEEL Maintain Buy CMP 237.75 Target 316

25.03.2022 - CLSA on ZEEL Maintain Buy CMP 295.60 Target 380
03.02.2022 - CLSA on ZEEL Maintain Buy CMP 292 Target 427
23.12.2021 - Motilal Oswal On Zeel Upgrade Buy - Target 425
23.12.2021  CITI - buy with target price of 395
23.12.2021  CLSA buy with target price of 415
23.12.2021 MOSL - upgrade to buy target price of 425
23.12.2021 Elara - buy with target price of 450
15.12.2021 - CLSA on Zeel - Maintain Buy - Cmp 372 Target 415

CLSA ON ZEE ENT : 21.05.2021

* MAINTAIN BUY TARGET: 306
* Zee Ent's Q4 ahead of estimates and ad revenue up 9% YOY, CLSA says
* Q4 Ahead Of Estimates And Ad Revenue Up 9% YoY
* Co Sees Rapid Recovery In Ad Revenue If Lockdowns Not Extended
* Balancesheet Cash Has Increased To 21,860 Cr From 1,000 Cr In FY20
* Risk-reward Attractive At Current Valuations

GS ON ZEE ENT : 21.05.2021

* MAINTAIN NEUTRAL TARGET: 208 (PREVIOUS TARGET: 225)
* Goldman Sachs forecasts a 5% FY20-25 revenue CAGR (8% FY21-25 CAGR) for Zee Ent after the media major announced its Q4 results yesterday
* Revenue Growth Of 1% YoY Is 7% Below Our Estimate
* Expect Growth Outlook For Zee To Stay Challenged
* Forecast A 5% FY20-25 Revenue CAGR (8% FY21-25 CAGR)
* Television Advertisement Will Continue To Lose Share To Digital
* Make 7-10% Cuts To Our EBITDA Estimates

UBS ON ZEE ENT : 21.05.2021

* MAINTAIN BUY TARGET: 250
* Healthy ad recovery by Zee Ent, but 2nd COVID wave could negatively impact FY22, UBS says
* Healthy Ad Recovery, But 2nd COVID Wave Could Negatively Impact FY22
* 'If Current Wave Does Not Go Into Q2, Double-digit Growth Is Achievable'

CLSA ON ZEE : 21.05.2021

* Maintain BUY, Target at Rs 306/share
* Q4 India ad revenue up 9% YoY
* Cash rises to Rs 1,860 cr & stock at 12x PE
* Resilient business and a compelling valuation; Zee to pull back investment in the 80%-owned SugarBox

ERIS

ERIS(Eris Lifesciences Ltd) 18.01.2023 -  Macquarie  on  ERIS Maintain Outperform CMP 625.75 Target 830